For the year ending 2025-12-31, ZVRA had $28,621K increase in cash & cash equivalents over the period. -$2,433K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenue, net | 106,470 |
| Research and development directly identified to programs-Direct Operating Costs | 7,710 |
| Research and development directly identified to programs-Indirect Operating Costs | 5,033 |
| Selling, general and administrative identified to programs-Direct Operating Costs | 26,755 |
| Selling, general and administrative identified to programs-Indirect Operating Costs | 50,861 |
| Impairment of intangible assets | 58,710 |
| Income tax expense | 3,449 |
| Interest income | 7,573 |
| Depreciation and amortization expense | 4,054 |
| Interest expense | 7,977 |
| Other (income) expense, net | -133,735 |
| Net income (loss) | 83,229 |
| Stock-based compensation expense | 12,634 |
| Impairment of intangible assets | 58,710 |
| Inventory obsolescence charge | 11,681 |
| Income tax expense | 3,449 |
| Depreciation and amortization expense | 4,054 |
| Non-cash interest expense | 2,649 |
| Non-cash lease expense | 602 |
| Fair value adjustment related to warrant and cvr liabilities | -2,178 |
| Accretion on investments | 3,128 |
| Fair value adjustment related to investments | -149 |
| Loss on sublease and disposal of property and equipment | 63 |
| Consulting fees paid in common stock | 75 |
| Loss on foreign currency exchange rates | -1,548 |
| Gain on sale of prv | 148,325 |
| Accounts and other receivables | 11,977 |
| Prepaid expenses and other current assets | 2,943 |
| Inventories | 1,305 |
| Other long-term assets | -451 |
| Accounts payable and accrued expenses | -15,587 |
| Discount and rebate liabilities | 6,683 |
| Operating lease liabilities | -675 |
| Other liabilities | -1,159 |
| Net cash used in operating activities | -1,598 |
| Purchases of property and equipment | 835 |
| Disposals of property and equipment | 448 |
| Purchases of investments | 309,986 |
| Maturities of investments | 178,500 |
| Proceeds from sale of prv | 150,000 |
| Payment of royalty to xoma | 0 |
| Net cash provided by (used in) investing activities | 18,127 |
| Proceeds from issuance of debt, net of lender fees | 0 |
| Repayment of debt | 0 |
| Proceeds from insurance financing arrangements | 0 |
| Proceeds from employee stock purchase plan | 615 |
| Proceeds from issuance of stock | 0 |
| Proceeds from issuance of common stock for options exercised | 3,182 |
| Proceeds from issuance of common stock for warrants exercised | 8,639 |
| Payments of principal on insurance financing arrangements | 372 |
| Payment of deferred financing costs | 0 |
| Net cash provided by financing activities | 12,064 |
| Effect of exchange rate changes on cash and cash equivalents | 28 |
| Net increase (decrease) in cash and cash equivalents | 28,621 |
| Cash and cash equivalents, beginning of period | 33,785 |
| Cash and cash equivalents, end of period | 62,406 |
ZEVRA THERAPEUTICS, INC. (ZVRA)
ZEVRA THERAPEUTICS, INC. (ZVRA)